Montréal, Québec – [June 17, 2025] – Corealis Pharma Inc., a leading Canadian Contract Development and Manufacturing Organization (CDMO) specializing in Oral Solid Dose (OSD), is proud to be representing Québec’s thriving life sciences ecosystem at the BIO International Convention 2025, taking place this week in Boston, Massachusetts.
Represented by CEO David Leroux-Petersen and David Kwajewski, the Corealis team joins a robust delegation of over 100 participants from 45 companies and 15 key organizations, spotlighting Québec’s leadership in global pharmaceutical innovation, biotech, and health technologies.
As part of the Québec delegation, Corealis is exhibiting at booth #1048, where the team is engaging with international partners, showcasing its expertise in formulation development and clinical supply manufacturing, and exploring opportunities for strategic collaboration.
“BIO 2025 is a premier global platform to highlight the strength and innovation of Québec’s life sciences sector,” said David Leroux-Petersen, Director of Business Development at Corealis. “We are proud to contribute our CDMO capabilities to the broader mission of advancing pharmaceutical development and building global partnerships.”
This initiative is led by Investissement Québec International, with the support of the Québec Government Office in Boston and the Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE).
About Corealis Pharma Inc.
Corealis Pharma Inc. is a privately held, GMP-compliant CDMO based in Laval, Québec, Canada. Specializing in oral solid dosage forms, Corealis provides customized formulation development, clinical supply manufacturing, and analytical services to biopharmaceutical companies worldwide. Known for its flexibility, scientific expertise, and quality-driven approach, Corealis is a trusted partner in the development of complex drug products.
